Correction to: Dinutuximab beta in high-risk neuroblastoma:
a proﬁle of its use
Katherine A. Lyseng-Williamson
Published online: 6 June 2018
Ó Springer International Publishing AG, part of Springer Nature 2018
Correction to: Drugs Ther Perspect
The Acknowledgements section on the last page should
‘‘The manuscript was reviewed by: P.F. Ambros, Chil-
dren’s Cancer Research Institute, St. Anna Kinderkrebs-
forschung, Vienna, Austria; F.H. Felix, Pediatric Cancer
Center, Hospital Infantil Albert Sabin, Fortaleza, Brazil; R.
Kebudi, Division of Pediatric Hematology-Oncology,
Cerrahpas¸a Medical Faculty & Oncology Institute, Istan-
bul, Turkey; H.B. Lindsay, Pediatric Hematology/Oncol-
ogy, Baylor College of Medicine, Houston, TX, USA; J.
Morales, Pharmacy Department, Hospital Dr Luis Calvo
Mackenna, Santiago, Chile. During the peer review pro-
cess, EUSA Pharma (UK) Limited, the marketing-autho-
rization holder of dinutuximab beta, was offered an
opportunity to provide a scientiﬁc accuracy review of their
data. Changes resulting from comments received were
made on the basis of scientiﬁc and editorial merit.
The original article has been corrected.
The original article can be found online at https://doi.org/10.1007/
& Katherine A. Lyseng-Williamson
Springer, Private Bag 65901, Mairangi Bay, 0754 Auckland,
Drugs Ther Perspect (2018) 34:288